FINWIRES · TerminalLIVE
FINWIRES

CIBCは第1四半期決算発表後、PrairieSky Royaltyの目標株価を32.75ドルに引き上げ、投資判断を「中立」に据え置いた。

-- CIBCキャピタル・マーケッツは、プレーリースカイ・ロイヤルティ(PSK.TO)の株式に対する投資判断を「中立」に据え置きつつ、同社の第1四半期決算発表を受け、目標株価を1株当たり31.75ドルから32.75ドルに引き上げた。 アナリストのジェイミー・クビク氏は、カナダ西部を拠点とするこの石油・ガスロイヤルティ会社が、2026年第1四半期の1株当たりキャッシュフローが市場予想を上回ったと報告した。これは、同四半期における多額のボーナス支給が要因となっている。このボーナス支給は、予想を下回った原油生産量を相殺するもので、原油生産量は2025年第4四半期からわずかに減少し、3四半期連続の減少となった。 アナリストらは、同社のデュヴァーネイ鉱区における掘削活動が過去最高水準に達しており、第2四半期から原油生産量が上昇に転じると予想されると述べた。また、2026年の1株当たりキャッシュフロー予想はほぼ据え置きだが、多額のボーナス支給が業界全体の掘削活動を促進する可能性があるため、企業価値評価は若干引き上げられたと付け加えた。 「WCSB(西カナダ堆積盆地)の主要な石油・ガス田におけるリース活動により、PrairieSkyの有機的成長の可能性は引き続き高く評価しています。現在の目標株価に基づくと、他のアウトパフォーマー銘柄に比べて株価の上昇余地は限定的であるため、現時点では中立の評価を維持します」とKubik氏は述べた。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703